Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Discover Emerging Technologies Driving the Future of Global Markets (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Mural Oncology PLC MURA

Healthcare Biotechnology
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company’s lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat... see more

Recent & Breaking News (NDAQ:MURA)

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 2, 2024

Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors

GlobeNewswire July 31, 2024

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 2, 2024

Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference

GlobeNewswire June 5, 2024

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 4, 2024

Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting

GlobeNewswire May 23, 2024

Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire May 14, 2024

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 3, 2024

Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire April 24, 2024

Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting

GlobeNewswire April 9, 2024

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 4, 2024

Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update

GlobeNewswire March 26, 2024

Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire March 5, 2024

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 4, 2024

Mural Oncology to Present at the TD Cowen 44th Annual Health Care Conference

GlobeNewswire February 27, 2024

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 5, 2024

Mural Oncology Announces Enhancements to Late-Stage Clinical Trials

GlobeNewswire January 8, 2024

Podcasts